Developer docs
API playgroundTry for free, no card

Search company profiles

Lava Therapeutics

Full company profile

uuid00008ni

Namestring
Lava Therapeutics
Legal namestring
LAVA Therapeutics N.V.
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Lava Therapeutics N.V. was a clinical-stage biotechnology company developing T cell engagers (TCEs), a class of bispecific immunotherapies designed to bridge a patient's T cells to tumor cells and trigger targeted cancer cell destruction. Incorporated in the Netherlands and headquartered in Utrecht, the company was founded in 2016 and went public in 2021 via a SPAC merger, trading on Nasdaq under the ticker LVTX. The platform progressed from early 1+1 bispecific formats toward more complex 2+1 and trispecific (1+1+1) architectures intended to improve tumor selectivity, address antigen heterogeneity, and modulate T cell activation.

The pipeline was oriented toward hematologic malignancies — including B-cell ALL and lymphoma — and the company had signaled intent to extend the platform into autoimmune disease indications. Because LAVA was pre-commercial, its prospective revenue model was based on future licensing and royalties rather than product sales. Prior to any commercial launch, a clinical trial failure prompted operational downsizing.

In August 2025, XOMA Royalty Corporation announced a share purchase agreement to acquire LAVA; in October 2025 the cash component was reduced and the tender deadline extended. The acquisition closed on November 21, 2025, with shareholders receiving cash and contingent value rights, after which LAVA became a wholly-owned subsidiary of XOMA Royalty and was delisted from Nasdaq.

Short descriptiontext

Lava Therapeutics was a clinical-stage biotech that developed bispecific and trispecific T cell engager immunotherapies for cancer and autoimmune diseases. The company was acquired by XOMA Royalty Corporation in November 2025 and delisted from Nasdaq.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersUtrecht, Netherlands
HQ citystring
Utrecht
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
bispecific antibodies, T cell engagers, cancer immunotherapy, gamma-delta T cells, bispecific antibody platform
Industry1 code
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Bispecific Antibody Therapeutics / Cancer Immunotherapy
No data
Revenue model1 record
1Biopharmaceutical Development
TypeLicensing Royalties
Description

As a clinical-stage biotech, LAVA Therapeutics was developing T cell engager therapies for cancer treatment. The company had not yet commercialized products and was acquired by XOMA Royalty before achieving product revenue.

globenewswire.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Lava Therapeutics developed bispecific T cell engager (TCE) immunotherapies that bridge T cells to tumor cells to trigger targeted cancer cell destruction. The platform progressed from 1+1 bispecific formats to next-generation 2+1 and trispecific (1+1+1) designs intended to improve tumor selectivity and address challenges such as antigen heterogeneity, cytokine release syndrome, and short half-life. Primary indications targeted hematologic malignancies including B-cell ALL and lymphoma, with potential applications in solid tumors and autoimmune diseases.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Lava Therapeutics is a clinical-stage biotech company specializing in innovative immunotherapies for cancer and autoimmune diseases. The company was developing T cell engager (TCE) bispecific immunotherapies, leveraging next-generation formats to bridge T cells to tumor cells for targeted cancer cell destruction. Following XOMA Royalty's acquisition completed in November 2025, the company has been delisted from Nasdaq.

Product and service1 record
1Bispecific gamma-delta T cell engager (TCE) pipeline
CategoryBispecific antibody therapeutics / cancer immunotherapy pipeline
Description

Proprietary clinical-stage pipeline of bispecific and trispecific T cell engagers designed to redirect T cells to tumor cells for targeted cancer cell destruction, developed for oncology indications such as B-cell acute lymphoblastic leukemia and lymphoma. Targeted at biopharma partners and ultimately oncology patients via future commercialization partners.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lava Therapeutics

Bispecific Antibody Therapeutics / Cancer Immunotherapylavatherapeutics.com

Lava Therapeutics was a clinical-stage biotech that developed bispecific and trispecific T cell engager immunotherapies for cancer and autoimmune diseases. The company was acquired by XOMA Royalty Corporation in November 2025 and delisted from Nasdaq.

What Lava Therapeutics does

Lava Therapeutics N.V. was a clinical-stage biotechnology company developing T cell engagers (TCEs), a class of bispecific immunotherapies designed to bridge a patient's T cells to tumor cells and trigger targeted cancer cell destruction. Incorporated in the Netherlands and headquartered in Utrecht, the company was founded in 2016 and went public in 2021 via a SPAC merger, trading on Nasdaq under the ticker LVTX. The platform progressed from early 1+1 bispecific formats toward more complex 2+1 and trispecific (1+1+1) architectures intended to improve tumor selectivity, address antigen heterogeneity, and modulate T cell activation.

The pipeline was oriented toward hematologic malignancies — including B-cell ALL and lymphoma — and the company had signaled intent to extend the platform into autoimmune disease indications. Because LAVA was pre-commercial, its prospective revenue model was based on future licensing and royalties rather than product sales. Prior to any commercial launch, a clinical trial failure prompted operational downsizing.

In August 2025, XOMA Royalty Corporation announced a share purchase agreement to acquire LAVA; in October 2025 the cash component was reduced and the tender deadline extended. The acquisition closed on November 21, 2025, with shareholders receiving cash and contingent value rights, after which LAVA became a wholly-owned subsidiary of XOMA Royalty and was delisted from Nasdaq.

Lava Therapeutics firmographics

Firmographics
Name
Lava Therapeutics
Legal name
LAVA Therapeutics N.V.
Website
https://lavatherapeutics.com
Company type
Public
Founded year
2016
Operating status
Acquired
Headcount range
11–50 employees
Short description
Lava Therapeutics was a clinical-stage biotech that developed bispecific and trispecific T cell engager immunotherapies for cancer and autoimmune diseases. The company was acquired by XOMA Royalty Corporation in November 2025 and delisted from Nasdaq.
Ownership category
akta.pro rank

Lava Therapeutics industry classification

Industry
Product category
Bispecific Antibody Therapeutics / Cancer Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Bispecific antibodies
  • T cell engagers
  • Cancer immunotherapy
  • Gamma-delta T cells
  • Bispecific antibody platform

Where Lava Therapeutics is headquartered

Location

Headquarters

HQ city
Utrecht
HQ country
Netherlands
HQ region
Europe

Markets served

Lava Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Biopharmaceutical Development: As a clinical-stage biotech, LAVA Therapeutics was developing T cell engager therapies for cancer treatment. The company had not yet commercialized products and was acquired by XOMA Royalty before achieving product revenue.

Marketing channels1 record

Lava Therapeutics product offering

Product offering

Core offering

Lava Therapeutics developed bispecific T cell engager (TCE) immunotherapies that bridge T cells to tumor cells to trigger targeted cancer cell destruction. The platform progressed from 1+1 bispecific formats to next-generation 2+1 and trispecific (1+1+1) designs intended to improve tumor selectivity and address challenges such as antigen heterogeneity, cytokine release syndrome, and short half-life. Primary indications targeted hematologic malignancies including B-cell ALL and lymphoma, with potential applications in solid tumors and autoimmune diseases.

Product overview

Lava Therapeutics is a clinical-stage biotech company specializing in innovative immunotherapies for cancer and autoimmune diseases. The company was developing T cell engager (TCE) bispecific immunotherapies, leveraging next-generation formats to bridge T cells to tumor cells for targeted cancer cell destruction. Following XOMA Royalty's acquisition completed in November 2025, the company has been delisted from Nasdaq.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bispecific gamma-delta T cell engager (TCE) pipeline Proprietary clinical-stage pipeline of bispecific and trispecific T cell engagers designed to redirect T cells to tumor cells for targeted cancer cell destruction, developed for oncology indications such as B-cell acute lymphoblastic leukemia and lymphoma. Targeted at biopharma partners and ultimately oncology patients via future commercialization partners.

Companies that use Lava Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Lava Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Lava Therapeutics partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Lava Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Lava Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lava Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Lava Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lava Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lava Therapeutics

What does Lava Therapeutics do?

Lava Therapeutics developed bispecific T cell engager (TCE) immunotherapies that bridge T cells to tumor cells to trigger targeted cancer cell destruction. The platform progressed from 1+1 bispecific formats to next-generation 2+1 and trispecific (1+1+1) designs intended to improve tumor selectivity and address challenges such as antigen heterogeneity, cytokine release syndrome, and short half-life. Primary indications targeted hematologic malignancies including B-cell ALL and lymphoma, with potential applications in solid tumors and autoimmune diseases.

Is Lava Therapeutics a public or private company?

Lava Therapeutics is a public company. It is classified as corporate owned and is currently acquired.

When was Lava Therapeutics founded?

Lava Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is Lava Therapeutics based?

Lava Therapeutics is headquartered in Utrecht, Netherlands, in the Europe region.

How does Lava Therapeutics make money?

One revenue line is on record: biopharmaceutical Development.

Does Lava Therapeutics have an API?

No public API is recorded for Lava Therapeutics.

What industry is Lava Therapeutics in?

Lava Therapeutics's product category is Bispecific Antibody Therapeutics / Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireXOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.XOMA Royalty completed its acquisition of LAVA Therapeutics, paying $1.04 per share in cash and a non-transferrable contingent value right. The CVR entitles holders to 75% of net proceeds from LAVA's partnered assets and up to $0.23 per CVR. LAVA's shares will be delisted from Nasdaq.GlobeNewswireXOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.XOMA Royalty completed its acquisition of LAVA Therapeutics, paying $1.04 cash per share plus a non-transferrable contingent value right. The CVR grants 75% of net proceeds from LAVA's partnered assets and unpartnered programs, plus up to $0.23 per CVR for potential liabilities. LAVA's shares will be delisted from Nasdaq.Investing.comLava Therapeutics shares delisted from Nasdaq following completion of acquisition By Investing.comLava Therapeutics shares were delisted from Nasdaq after XOMA Royalty Corporation completed its acquisition, acquiring about 91.1% of outstanding shares at $1.04 per share plus a contingent value right. The company plans to terminate reporting obligations by filing Form 15 with the SEC on December 1, 2025.GlobeNewswireLAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from NasdaqXOMA Royalty Corporation's tender offer to acquire LAVA Therapeutics N.V. has exceeded the minimum tender condition, with 22,877,463 shares (approximately 87% of outstanding shares) validly tendered prior to the November 12, 2025 deadline. LAVA has submitted notice to voluntarily delist from Nasdaq, with shares expected to be suspended from trading on or about November 21, 2025, contingent upon XOMA Royalty acquiring all validly tendered shares. A subsequent offering period runs until November 20, 2025, allowing remaining shareholders to tender their shares.GlobeNewswireLAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 DeadlineLAVA Therapeutics reminded shareholders to tender shares for XOMA Royalty's offer, which expires November 12, 2025. The board recommends tendering, warning that failure could lead to liquidation with proceeds significantly less than the offer's cash consideration.GlobeNewswireLAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 DeadlineXOMA Royalty Corporation has extended its tender offer to acquire all outstanding common shares of LAVA Therapeutics N.V. until November 12, 2025, and LAVA's Board unanimously recommends shareholders tender their shares before the deadline. If insufficient shares are tendered, the offer cannot be completed, and LAVA's Board may pursue liquidation and dissolution, with management estimating total liquidation proceeds would be significantly less than the offer cash consideration. The extension follows the original August 4, 2025 agreement between the parties.PR NewswireShareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase AgreementThe Ademi Firm, a shareholder litigation law firm, announced an investigation into LAVA Therapeutics N.V. (Nasdaq: LVTX) regarding an amendment to its purchase agreement with XOMA Royalty that reduces per-share cash consideration from a previously agreed range of $1.16-$1.24 to $1.04. The amendment also lowers the minimum net-cash closing condition from $31.5 million to $24.5 million and introduces non-transferable contingent value rights, while insiders are set to receive substantial change of control benefits. The law firm is examining whether the Lava board fulfilled its fiduciary duties to public shareholders, noting that the transaction agreement imposes significant penalties that unreasonably restrict the company from accepting competing bids.GlobeNewswireXOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase AgreementXOMA Royalty Corporation and LAVA Therapeutics N.V. have agreed to amend their previously announced share purchase agreement, reducing the cash consideration to $1.04 per share from the originally agreed range of $1.16–$1.24, while adding updated contingent value right (CVR) terms including new rights tied to potential liability determinations worth up to approximately $0.23 per CVR. The companies also lowered the minimum net-cash closing condition to $24.5 million from $31.5 million, citing updated estimates of expected cash balance and potential liabilities at closing. The tender offer has been extended to November 12, 2025, and LAVA's Extraordinary General Meeting has been rescheduled to November 7, 2025, with the acquisition expected to close in Q4 2025 subject to shareholder approval and other customary conditions.BioSpaceXOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.XOMA Royalty Corporation has extended its tender offer to acquire all outstanding shares of LAVA Therapeutics N.V. until October 17, 2025, pushing back the original expiration date of October 3, 2025. The acquisition, expected to close in Q4 2025, requires tender of at least 80% (or 75% in certain cases) of LAVA's shares and includes cash consideration plus non-transferable contingent value rights tied to 75% of net proceeds from LAVA's partnered assets and any future out-licensing or sale of unpartnered programs. LAVA shareholders who have already tendered shares do not need to take additional action, and a shareholder meeting is scheduled prior to early November 2025 to vote on the proposed transaction.